Xu Cao

US Patent:

20210205638, Jul 8, 2021

Filed:

Mar 3, 2021

Appl. No.:

17/191419

Inventors:

- Baltimore MD, US
Xu CAO - Ellicott City MD, US

International Classification:

A61P 19/10
A61P 35/00
A61K 38/29

Abstract:

The present invention provides methods for treatment of IVD degeneration and/or LDD in a subject having symptoms of IVD degeneration and/or LDD comprising administering to the subject an effective amount of Parathyroid hormone (PTH) or a functional fragment or analog thereof. Reduction in IVD degeneration and regeneration of IVD using the inventive methods is also provided.

US Patent:

20200339671, Oct 29, 2020

Filed:

Oct 30, 2018

Appl. No.:

16/760731

Inventors:

- Baltimore MD, US
Xu Cao - Ellicott City MD, US

International Classification:

C07K 16/22
A61P 19/08

Abstract:

The present inventors have uncovered the nature of heterotopic ossification HO progression as an excessive activation of TGF-β in recruitment of MSCs for osteogenesis in coupling with type H vessel formation. Systemic injection of TGF-β neutralizing antibody using the methods of the present invention, effectively attenuated HO progression in multiple different HO animal models. The present invention provides methods for prophylaxis and treatment of HO and also rare genetic diseases such as fibrodysplasia ossificans progressive (FOP) (also known as myositis ossificans progressive) and progressive osseous heteroplasia (POH).by inhibition of TGF-β.

US Patent:

20200283513, Sep 10, 2020

Filed:

Nov 13, 2018

Appl. No.:

16/763597

Inventors:

- Baltimore MD, US
Xu Cao - Ellicott City MD, US

International Classification:

C07K 16/22
A61K 31/4178

Abstract:

The present invention shows that TGF-β is activated in tendon-bone insertion in both a semi-Achilles tendon transection mouse model and a dorsiflexion immobilization (DI) mouse model of enthesopathy. High concentrations of active TGF-β recruited mesenchymal stromal/stem cells (MSCs) and led to excessive vessel formation, bone deterioration and fibrocartilage calcification cation. The invention provides uses and methods for prophylaxis and treatment of enthesopathies by inhibition of TGF-β.

US Patent:

20200222419, Jul 16, 2020

Filed:

Aug 29, 2018

Appl. No.:

16/643672

Inventors:

- Baltimore MD, US
Xu Cao - Ellicott City MD, US

International Classification:

A61K 31/55
A61P 19/10

Abstract:

The present invention provides methods for manipulating epigenetic factors to treat pediatric or juvenile osteoporosis. Specifically, the present invention provides methods for the application of H3K27 demethylase inhibitors in pediatric or juvenile subjects with osteoporosis. Thus, the present invention provides methods of administration of the H3K27 demethylase inhibitor, GSK-J4, to pediatric or juvenile subjects to effectively inhibit primary and secondary pediatric osteoporosis, especially for long-term glucocorticoid treated patients (juvenile rheumatoid disorders, Crohn's disease, nephrotic syndrome, and Duchenne muscular dystrophy) and patients who have compromised mobility (cerebral palsy, Rett syndrome, Duchenne muscular dystrophy, spina bifida, and spinal muscular atrophy).

US Patent:

20190381341, Dec 19, 2019

Filed:

Feb 1, 2018

Appl. No.:

16/482897

Inventors:

- Baltimore MD, US
Xu CAO - Ellicott City MD, US

International Classification:

A61P 19/10
A61P 35/00
A61K 38/29

Abstract:

The present invention provides methods for treatment of IVD degeneration and/or LDD in a subject having symptoms of WD degeneration and/or LDD comprising administering to the subject an effective amount of Parathyroid hormone (PTH) or a functional fragment or analog thereof. Reduction in IVD degeneration and regeneration of IVD using the inventive methods is also provided.